



Scientific Chair:

Nathalie Albert, Munich

Scientific Co-Chair:

Matthias Preusser, Vienna



DIAGNOSTIC AND THERAPEUTIC INNOVATIONS IN THE ERA OF PRECISION MEDICINE – NUCLEAR MEDICINE MEETS NEURO-ONCOLOGY

POCKET PROGRAM

NMN Symposium: Precision Medicine

09.-10. May 2025 / Vienna, Austria

Palais Ferstel

www.nmn-society.org

Nuclear Medicine and Neurooncology (NMN)



An established global key
player in the **radioisotope
& radiopharmaceutical** field.



Find out
more about
us and our
products.

www.itm-radiopharma.com

Follow us:  

The logo consists of a small dot above the letters 'itm' in a bold, sans-serif font.

PASSION FOR PRECISION



2	PRESIDENTIAL ADDRESS
3	BOARD - SCIENTIFIC COMMITTEE – ORGANISATION
4	PROGRAM OVERVIEW
4	FRIDAY, 09. MAY 2025
6	SATURDAY, 10. MAY 2025
9	POSTER INFORMATION
15	SPONSORS
16	GENERAL INFORMATION
18	NETWORKING EVENT
19	FUTURE NMN SYMPOSIUM

PRESIDENTIAL ADDRESS

Dear colleagues,

We are delighted to welcome you in Vienna for the second “**Diagnostic and Therapeutic Innovations in the Era of Precision Medicine – Nuclear Medicine Meets Neuro-Oncology (NMN)**” Symposium taking place from **May 09th - 10th, 2025!**

With the NMN Symposium we aim to provide a prime platform for networking and discussion of the most novel data in the field of molecular imaging and theranostics in Neuro-Oncology. The program of the symposium will highlight the most recent findings in basic, translational, and clinical science in this exciting and evolving field of research. We are very proud and grateful for the outstanding speaker panel and faculty with top experts from all over the world and from different specialties! Furthermore, we are very happy to have received 60 high quality submissions of original contributions that will be shared in oral and poster presentations and will surely lead to lively exchange and generate new cooperations and research ideas. A Coffee with the Editors session provides the opportunity to interact with editors of top journals and to discuss areas of interest and publication strategies.

We thank the NMN Meeting Office, the Scientific Committee, and all supporters for the hard work and fantastic collaboration in organizing the symposium! Let's enjoy together the exciting scientific exchange during the main symposium program, as well as the strengthening of collaborations and friendships during our networking activities!

Welcome to Vienna - we are very excited about so many bright brains coming together for the NMN Symposium 2025!

Nathalie L. Albert
Scientific Chair

Matthias Preusser
Scientific Co-Chair

NMN Board

Matthias Preusser, Vienna, Chairperson
Nathalie L. Albert, Munich, Secretary


NMN Scientific Committee

Nathalie L. Albert, Munich, Scientific Chair
Matthias Preusser, Vienna, Scientific Co-Chair
Martin van den Bent, Rotterdam
Michael Weller, Zurich
Jolanta Kunikowska, Warsaw
Emilie Le Rhun, Zurich
Norbert Galldik, Cologne
Marcus Hacker, Vienna
Giuseppe Minniti, Rome
Roberta Rudà, Turin
Karl Rössler, Vienna

Patrick Wen, Boston
Eng-Siew Koh, Sydney
Erik Sulman, New York
Jörg-Christian Tonn, Munich
Wim Oyen, Milan/Arnhem
Andrew Scott, Melbourne
Anna Berghoff, Vienna
Nelleke Tolboom, Utrecht
Francesco Cicone, Catanzaro
Evanthia Galanis, Rochester

NMN Symposium Organizer

Nuclear Medicine and Neurooncology c/o WMA GmbH
Alser Strasse 4
1090 Vienna, Austria



Scientific Management, Exhibition, Sponsorship, General Organization and Logistics

WMA GmbH
Lydia Schnedl
Juliana Tusa
T: +43 1 405 13 83 – 19
E: nmn@wma.co.at
W: www.nmn-society.org



PROGRAM OVERVIEW

Friday, 09. May 2025

All times refer to Central European Summer Time (CEST).

09:45 – 10:00 Welcome and Introduction

- **Nuclear Medicine meets Neuro-Oncology**
Nathalie L. Albert (Munich), Matthias Preusser (Vienna)

10:00 – 12:00 Radioligand therapy – the future of precision oncology

Chairs: Eng-Siew Koh (Sydney), Tim Cloughesy (Los Angeles)

- **RLT works – current evidence.**
Michael Hofman (Melbourne) – 20+10'
- **Next generation RLT – trends in nuclear medicine.**
Marcus Hacker (Vienna) – 20+10'
- **Bringing RLT into the CNS – a promising concept in neuro-oncology?**
Nathalie Albert (Munich) – 20+10'
- **Panel discussion**
All session speakers
+ Vassilis Golfopoulos (Brussels) + Pierre Demolis (Paris) – 30'

12:00 – 13:00 NMN Lunch

13:00 – 14:00 Understanding theranostics

Chairs: Wim Oyen (Arnhem/Milan), Jörg Tonn (Munich)

- **Radiopharmaceuticals explained**
Karolien Goffin (Leuven) – 15+5'
- **From reactor to patient – how do we get radionuclides into clinical routine?**
Andrew Scott (Melbourne) – 15+5'
- **Panel discussion: All you need to know about RLT – frequently asked questions in clinical routine.**
All session speakers
+ Francesco Ciccone (Catanzaro) + Roberta Rudà (Turin) – 20'

14:00 – 15:00 Proffered papers I: Hot data and burning questions

Chairs: Jolanta Kunikowska (Warsaw), Giuseppe Minniti (Rome)

- ♦ **Rhenium obisbameda (reyobiq) in leptomeningeal metastases –**
Andrew Brenner (San Antonio), [Abstract No. 61](#) – 5+3'
- ♦ **Somatostatin receptor–targeted radionuclide therapy for meningiomas: factors associated with therapeutic response and initial dosimetric data –**
Antoine Verger (Nancy), [Abstract No. 10](#) – 5+3'
- ♦ **Intraarterial administration of peptide receptor radionuclide therapy in patients with advanced meningioma: initial safety and efficacy –**
Adriana Amerein (Augsburg), [Abstract No. 28](#) – 5+3'
- ♦ **Approaches to enhance the delivery of EGFR-affibody based agents for radionuclide therapy with terbium-161 –**
Dawoud Dar (Sutton), [Abstract No. 22](#) – 5+3'
- ♦ **Imaging a potential lymphatic link between the intracranial and cervical compartments in patients receiving intracavitary radioimmunotherapy & A Phase 1 trial to determine the maximum tolerated dose and patient-specific dosimetry of fractionated intracavitary radioimmunotherapy with Lutetium-177 labeled 6A10 Fab fragments in patients with glioblastoma – preliminary results from the first patient cohort –**
Michael Müther (Münster), [Abstract No. 25 & 26](#) – 5+3'

Friday, 09. May 2025

- ◊ Accelerate.eu: Astatine-211 Theranostic European Initiative – Hugo Levillain (Brussels), [Abstract No. 21](#) – 5+3'
- ◊ Assessment of Quality of life in cancer patients receiving radioligand therapy (RLT) – Mieke Van Hemelrijck (London), [Abstract No. 12](#) – 5+3'

15:00 – 15:45 NMN Coffee

15:45 – 17:00 Proffered papers II: Hot data and burning questions

Chairs: Martin van den Bent (Rotterdam), Andrew Scott (Melbourne)

- ◊ Combined Multiparametric MRI and 18F-FDOPA PET Imaging Features Strongly Predict Molecular Status, Malignant Transformation, and Survival in Gliomas – Timothy Cloughesy (Los Angeles), [Abstract No. 45](#) – 5+2'
- ◊ Prognostic stratification of newly diagnosed isocitrate dehydrogenase (IDH)-mutant gliomas by amino acid positron emission tomography (PET) – Maximilian Mair (Vienna), [Abstract No. 6](#) – 5+2'
- ◊ Metabolic heterogeneity in glioblastoma: correlating 18F-Fluciclovine PET uptake with RNA sequencing and metabolic pathway activity & Dynamic 18F-Fluciclovine PET and MRI Metrics for Predicting Survival in Glioblastoma – Ali Nabavizadeh (Wynnewood), [Abstract No. 23 & 24](#) – 5+2'
- ◊ Prognostic value of 18F-FET PET in patients with recurrent glioblastoma – Wietse Geens (Brussels), [Abstract No. 59](#) – 5+2'
- ◊ Comparing PET RANO 1.0 with MR RANO for a phase II clinical trial of 18F-DOPA-PET directed dose escalated radiotherapy for glioblastoma – Debra Brinkmann (Byron), [Abstract No. 41](#) – 5+2'
- ◊ Multi-site, prospective trial evaluating FET-PET In Glioblastoma (FIG) Study (TROG 18.06): Trial in progress – central nuclear medicine and radiation oncology review of FET-PET biologic target volume delineation for radiotherapy planning – Eng-Siew Koh (Sydney), [Abstract No. 20](#) – 5+2'
- ◊ Fully automated evaluation of FET PET in brain tumor patients – Philipp Lohmann (Juelich), [Abstract No. 13](#) – 5+2'
- ◊ Impact of preoperative somatostatin-receptor-targeted PET imaging on resection planning and surgical decision-making in meningiomas – Nina Teske (Munich), [Abstract No. 17](#) – 5+2'
- ◊ Expanding the role of [18F]FET PET-MRI beyond glioma: superior detection of small functional pituitary tumors – Sophie Veldhuijzen van Zanten (Rotterdam), [Abstract No. 37](#) – 5+2'
- ◊ Availability and use of PET in patients with brain tumours – a European Organisation for Research and Treatment of Cancer – Brain Tumour Group (EORTC-BTG) survey – Nathalie Albert (Munich), [Abstract No. 33](#) – 5+2'

17:00 – 18:30 Posters viewing: Science and Drinks

From 19:00 Networking Event “Heurigen”

For further information see page 18

PROGRAM OVERVIEW

Saturday, 10. May 2025

09:00 – 10:00 Coffee with the Editors

Karen O'Leary (Nature Medicine), Alexia-Ileana Zaromytidou (Nature Cancer), Ivana Nedić (The Lancet Group), Matthias Preusser (Neuro-Oncology), Joanne Clancy (Nature Communications)

10:00 – 12:00 Enhancing treatment efficacy

Chairs: Patrick Wen (Boston), Emilie Le Rhun (Zurich)

- **Intraarterial injections of therapeutic radioligands – challenges and opportunities.**
Arthur Braat (Utrecht) – 15+15'
- **Overcoming the blood-brain-barrier – what's the fuss about FUS?**
Adam Sonabend (Chicago) – 15+15'
- **Local applications of RLT – is this the way to go?**
Bogdana Suchorska (Heidelberg) – 15+15'
- **Enhancing radiosensitivity and overcoming treatment resistance**
Erik Sulman (New York) – 15+15'


12:00 – 13:30 NMN Lunch

13:30 – 15:00 Lessons learned from other disciplines

Chairs: Nelleke Tolboom (Utrecht), Anna Berghoff (Vienna)

- **The trialist's perspective: how to generate evidence.**
Michael Weller (Zurich) – 10+10'
- **The oncologist's perspective: adapting the success of antibody drug conjugates.**
Matthias Preusser (Vienna) – 10+10'
- **The neuropathologist's perspective: targets and biomarkers**
Felix Sahm (Heidelberg) – 10+10'
- **The non-oncological perspective: lessons learned from neurodegenerative disorders.**
Matthias Brendel (Munich) – 10+10'

15:00 – 15:45 NMN Coffee



Saturday, 10. May 2025


15:45 – 17:00 PET imaging of CNS tumors: must have or nice to have?

Chairs: Michael Weller (Zurich), Johnny Duerinck (Brussels)

- **Overview RANO PET working group activities**
Norbert Galldiks (Cologne) – 10+5'
- **Point-counterpoint debates**
- **Point: the case for amino acid PET imaging of glioblastoma**
Nathalie Albert (Munich) – 15'
- **Counterpoint: the case against amino acid PET imaging of glioblastoma**
Marjolein Geurts (Rotterdam) – 15'
- **Call to action: how to proceed**
Panel discussion + Pierre Demolis (Paris) – 30'

17:00 – 17:30 Conclusions and Farewell Drinks


Nathalie L. Albert (Munich), Matthias Preusser (Vienna)



All contents are as per date of printing (24. April 2025).

The up-to-date scientific program is available in the [online program](#) on the symposium website.

The organizer reserves the right to modify the program in case of external or unforeseen circumstances and cannot assume any liability. No refunds can be granted in case of cancellations of speakers, lack of space in the lecture room or any other incidents during the symposium which are beyond the control of the organizer.



Reimagining Nuclear Medicine

Transforming patients' lives by leading innovation

Novartis is reimagining medicine to improve and extend people's lives. We deliver high-value medicines that alleviate society's greatest disease burdens through **technology leadership in R&D** and novel access approaches. In our quest to find new medicines, we consistently rank among the world's top companies investing in research and development. About **108,000 people** of more than **140 nationalities** work together to bring Novartis products to nearly **800 million people** around the world.



Rich Oncology Pipeline

Targeting multiple
tumor types



Reimagining

Nuclear medicine by
developing drugs for targeted
radioligand therapy and
precision radioligand imaging

 NOVARTIS

Posters will be on display on both days in the Main lecture Hall/Großer Festelsaal on the 1st floor.

A dedicated **poster viewing session** is scheduled on **Friday, May 09, 2025 from 17.00-18.30h**. To enable discussion and interaction poster presenters or one of their group members are asked to be present at the poster board during this time.

A list of posters presented can be found from page 10 onwards.

Poster numbers will be shown on the poster boards.

Poster mounting and removal

Registration and poster mounting will be open from 08.45 on Friday morning, May 09, 2025. **All posters must be removed after the symposium on Saturday, May 10, 2025, until 18.00h.** Posters that have not been removed will be taken down and will not be stored or sent to the authors afterwards.

Please note: Posters may **not be hung up during the sessions**.

Only adhesive tape can be used to mount posters. Material will be available onsite.

Poster Topics

1. Brain Metastasis
2. Glioma
3. Lymphoma
4. Meningioma
5. Other

Abstracts

Abstracts presented at the **NMN Symposium 2025** are available on the symposium website.



POSTER INFORMATION


Poster List

Poster Nr.	Titel	First Name	Last Name	Country
1.01	Role of PET FET in monitoring of treatment brain metastasis	Elena	Gromova	<i>Russian Federation</i>
1.02	Symptomatic prostate-specific membrane antigen (PSMA) PET-positive radionecrosis following multimodality brain metastasis-directed treatment including [177Lu]Lu-PSMA-617	Brandon	Imber	<i>United States</i>
1.03	Metabolic and Molecular PET Profiling of Glioblastoma and Metastatic Brain Tumors: Key Markers for Differentiation	Keisuke	Miyake	<i>Japan</i>
1.04	Targeting fibroblast activation protein in brain metastases: development and evaluation of a novel alpha-ketoamide-based FAP radioligand	Petr	Vymola	<i>Czech Republic</i>
1.05	Application of the PET RANO BM 1.0 criteria in brain metastases: retrospective single center experience	Lilian	Wiegand	<i>Germany</i>
2.01	Measurable disease for response assessment in IDH-mutant glioma – a comparison of MRI-based (RANO 2.0) versus PET-based (PET RANO 1.0) assessment	Enio	Barci	<i>Germany</i>
2.02	18F-DOPA PET in Surgical Planning of High-Grade Gliomas: Volumetric Analysis, Comparison with intraoperative Fluorescence, and Histopathological Validation.	Andrea	Bianconi	<i>Italy</i>
2.03	Identifying residual tumor burden in postoperative glioblastoma: A comparative analysis of MR-based RANO resect classes vs. [18F]FET-PET	Jens	Blobner	<i>Germany</i>
2.05	Targeting low-density-lipoprotein-receptors in newly diagnosed or recurrent glioblastoma patients: A Phase I exploratory study and potential for theranostics	Ebrahim	Delpassand	<i>United States</i>
2.06	Validation of the PET-RANO Criteria in Pediatric Brain Tumors: Insights from FET-PET MRI Follow-Up	Cora	Hedrich	<i>Austria</i>
2.07	Probing the advantage of immuno-PET In advancing clinical theranostics for high-grade gliomas: A scoping review	Morohun-mubo	Ibiyo	<i>Nigeria</i>

2.08	A prospective phase I study of adjuvant [177Lu] Lu-PSMA-617 for PSMA-expressing IDH wildtype gliomas following chemoradiotherapy	Brandon	Imber	<i>United States</i>
2.09	Predicting the added value of [18F]FET PET in glioblastoma patients using MRI radiomics	Lena	Kaiser	<i>Germany</i>
2.10	Can MRI radiomics predict [18F]FET PET positivity in non-enhancing gliomas?	Lena	Kaiser	<i>Germany</i>
2.11	11C-Methionin PET for radiotherapy treatment planning in patients with rapid early progression after glioblastoma surgery: prospective phase II trial	Tomas	Kazda	<i>Czech Republic</i>
2.12	Expression of carbonic anhydrase type IX (CA IX) as target for radioligand therapy in gliomas and brain metastases	Maximilian	Mair	<i>Austria</i>
2.13	PSMA PET uptake patterns in brain tumors: comparative analysis of [68Ga]Ga-PSMA-11/ [18F]PSMA-1007 PET with [18F]FET PET and contrast-enhanced MRI	Maximilian	Mair	<i>Austria</i>
2.15	Comparative study of measurable disease according to PET RANO 1.0 vs. RANO 2.0 criteria at baseline after radiotherapy and at first progression in glioblastoma	Katharina	Müller	<i>Germany</i>
2.16	Locoregional distribution of [18F]-FET PET hypermetabolic foci in diffuse lower-grade insular glioma: a potential link to cancer neuroscience	Zeynep	Özdemir	<i>Germany</i>
2.17	A single arm monocentric phase II study to evaluate safety, tolerability, and preliminary efficacy of carrier-added 4-L-[131I]iodo-phenylalanine (131I-IPA), administered as sequential injections in patients with recurrent GBM concomitantly to 2nd line external radiation therapy-IPAX – Linz	Josef	Pichler	<i>Austria</i>
2.19	Is there a need for sex-sensitive [18F]FET PET evaluation? A retrospective study of sex-specific differences in [18F]FET uptake in glioma imaging	Isabelle	von Polenz	<i>Germany</i>
2.20	IPAX-2: Phase 1 safety and dose finding study of [131I]IPA plus standard of care in patients with newly diagnosed glioblastoma	Joseph	Pichler	<i>United States</i>
2.21	Clinical utility of [18F]FET PET in patients with circumscribed astrocytic glioma	Jan	Werner	<i>Germany</i>

POSTER INFORMATION

3.01	Rare Primary Intracranial Histiocytic Sarcoma in a Pediatric Case	Elif	Aslan	<i>Turkey</i>
3.02	The many faces of primary CNS T cell lymphoma: a multicentric, retrospective study of histopathologic, molecular and neuroimaging features	Katharina	Müller	<i>Germany</i>
3.03	CXCR4-targeted PET imaging of central nervous system lymphoma and glioma using [68Ga] Ga-Pentixafor	Jan	Werner	<i>Germany</i>
4.01	The Dural Tail in Meningiomas: Correlation of MRI, PET/CT, and neuropathological findings	Tobias	Greve	<i>Germany</i>
4.02	Efficacy and safety of 177Lu-DOTATATE treatment in patient with neurofibromatosis type 2 and multiple intracranial meningiomas, after several courses of radiotherapy – a case report.	Hanna	Grzbiela	<i>Poland</i>
4.03	Tumor dosimetry in patients receiving [177Lu] Lu-DOTATATE treatment for recurrent meningioma	Maximilian	Mair	<i>Austria</i>
5.01	Paraneoplastic Syndromes and Autoimmune Encephalitis: Medical Records Review and FDG-PET/CT Outcomes	Maurício	Baldissin	<i>Brazil</i>
5.02	How we can change scanning parameters but maintain image quality	Elena	Gromova	<i>Russian Federation</i>
5.03	Treatment challenges of primary CNS neuroendocrine tumors and the value of peptide receptor radionuclide therapy: A case report.	Zeynep	Özdemir	<i>Germany</i>
5.04	18F-FET uptake in the pons in children with a normal brainstem after radiotherapy	Daniil	Susin	<i>Russian Federation</i>
5.05	[18F]Fluorethyltyrosine positron emission tomography for localisation of corticotroph pituitary adenomas in the initial evaluation of Cushing's disease	Friederike	Völter	<i>Germany</i>



Focused and innovative player developing targeted therapies to treat cancer

Cancer causes more than one in six of all deaths, making it the second leading cause of death in the world, and numbers are on the rise. To address the growing need for therapeutic solutions, we have made oncology one of our priority innovation areas.

We invest close to 70% of our R&D budget in oncology, **with a view to becoming a focused and innovative player in rare cancer treatments.**

Discover Servier activities in oncology through our website





Making Bold Strides in Cancer

Innovating to deliver on the
potential of ADC technology.



We thank our valued partners for their support.

PLATINUM SPONSORS



GOLD SPONSORS



SILVER SPONSORS



GENERAL SPONSORS



TRAVEL SCHOLARSHIP & OTHER SPONSORS



GENERAL INFORMATION

Registration Opening Hours

Friday, May 09, 2025: 08:45 – 18:30 hrs
Saturday, May 10, 2025: 08:30 – 17:30 hrs

Location and Accessibility

Palais Ferstel

Strauchgasse 4, 1010 Vienna, Austria

The Palais Ferstel (Strauchgasse 4, 1010 Vienna) is located in the centre of Vienna. There are good public transport connections, and the Palais Ferstel is within easy reach from the following stations: Herrengasse (metro U3) and Schottentor (metro U2, tram 44). If arriving by car, there is underground parking at WIPARK Freyung Parkgarage and at Garage Am Hof | BEST IN PARKING.

We recommend using public transportation whenever possible.

Social Media

Stay connected!
Follow us on LinkedIn and subscribe to our newsletter for updates and news.
Join the conversation! Use the hashtag #NMN2025 for your posts.



Nuclear Medicine and
Neurooncology (NMN)



@nmnsymposium.bsky.social

Free-Wifi

Network: FREEWAVE

Cloakroom

Opening hours:
Friday, May 09, 2025: 08:45 – 19:00 hrs
Saturday, May 10, 2025: 08:30 – 18:00 hrs



Conference Policy

Badges

Permission to the symposium (scientific sessions, exhibition and poster area) is only permitted to registered participants. Therefore, wearing your badge throughout the entire symposium is mandatory!

Language

The official language is English (no simultaneous translation available).

Certificate of attendance

Confirmations of attendance will be issued via email to all participants after the symposium.

Catering

During the lunch breaks, a light lunch as well as coffee and tea will be offered free of charge to participants wearing name badges in the exhibition area.

During the afternoon coffee breaks, refreshments (coffee, tea and snacks) will be served free of charge to participants wearing name badges in the exhibition area.

Additionally, water will be provided for free and coffee will be provided during the day in the exhibition area.

Smoking policy

The NMN 2025 Symposium is officially a “no-smoking-congress”. Note that smoking is banned in public buildings and private businesses in Vienna (e.g. restaurants, shops, public transport, entertainment venues and workplaces).

Sustainability

The NMN is committed to environmental sustainability, a responsible use of resources and sustainable congress materials. The organizer therefore asks you to keep these aspects in mind, e.g. by using public transport to get to the venue and networking events.

On-site filming

We are happy to announce that an American film and television production company, Alliance Cinema, has commenced production on “The C-Story,” a feature documentary dedicated to illuminating the latest advancements in cancer treatment and research. Led by Emmy-nominated director Jim Milio, the film aims to educate and inspire cancer patients and their families by showcasing the newest and most transformative developments in oncology that are happening throughout the world. A team from the production is here to film and interview several of our esteemed colleagues during the symposium.

GENERAL INFORMATION

NETWORKING EVENT

Please note that the number of participants for the networking event is limited and advance registration is mandatory for the event. Admission will only be granted with a valid ticket. Check ticket availability at the registration desk.


No sponsoring is used to fund any part of the NMN Symposium 2025 Networking Event.

Location: 10er Marie
Ottakringer Str. 222/224, 1160 Vienna

Public transport: Metro U3 Station "Ottakring"
Tram 44 Station "Johannes Krawarik Gasse"

Date: Friday, May 09, 2025

Time: 19:00 – 23:00 hrs



Individual arrival.

The City of Vienna and the Mayor Dr. Michael Ludwig are hosting this evening.



RELIABLE IN PRODUCTION AND SERVICE



+49 228 925 88 30




csadacap.team@siemens-healthineers.com



Advanced Accelerator Germany GmbH,
Saime-Genc-Ring 18, 53121 Bonn, Germany

Advanced
Accelerator
Applications

A Siemens Healthineers
Company



Scientific Chair:
Nathalie Albert, Munich

Scientific Co-Chair:
Matthias Preusser, Vienna



SAVE
THE
DATE

NMN Symposium

07.-08. May 2026
Vienna, Austria

www.nmn-society.org

Nuclear Medicine and Neurooncology (NMN)



NMN



TRIALIST.

Fellowship

A Nuclear Medicine and Neurooncology program



Theranostics are emerging as novel treatment paradigm in Neuro-Oncology, but specific challenges need to be considered for clinical trials with radioligand therapies.^[1] The NMN Clinical **tRiaLiSt** Fellowship offers training and hands-on experience in clinical trial development for theranostic treatments in CNS tumors under the supervision of **Prof. Dr. Nathalie Albert** (Nuclear Medicine) and **Prof. Dr. Matthias Preusser** (Medical Oncology).

^[1] Albert et al., „Translating the theranostic concept to neuro-oncology: disrupting barriers“, Lancet Oncology 2024.”

AMOUNT AND DURATION



1 year fellowship at LMU Munich with training modules at Medical University of Vienna for **€50,000**

FELLOWSHIP CONTENT

- ✓ Clinical trial methodology and conduct: study design, endpoints, statistics, legal, ethics, project management
- ✓ Medical writing
- ✓ Presentation skills
- ✓ Research project: clinical trial protocol development, collection of supportive data in a companion project, peer-reviewed publication

APPLY NOW

Applicants are invited to send a:

- motivation letter (max. 2 pages)
- CV (max. 3 pages)
- publication list
- support letter, signed by the home institute applicant's department head (max. 2 pages)
- documents should be provided in english

The two-step selection is based on the application documents and an interview by the NMN Clinical tRiaLiSt Fellowship program heads.

REQUIREMENTS

- ✓ Applicants should be engaged in clinical research in the field of Nuclear Medicine or Neuro-Oncology
- ✓ Applicants should be proficient in English




Send your resume by **July 31st 2025** to
NMN@WMA.CO.AT



Visit our website
WWW.NMN-SOCIETY.ORG

Grant support:  **Telix**

NMN



TRIALIST.

Fellowship

A Nuclear Medicine and Neurooncology program

APPLY NOW

more information available at
www.nmn-society.org



THE
WORLD'S
LEADING
PROVIDER
OF NUCLEAR
MEDICINE

Drawing on over 100 years of proven experience, we aim to drive the nuclear medicine industry forward through excellence, reliability and unparalleled service.

CURIUMPHARMA.COM





Forschung,
Verantwortung
und medizinischer
Fortschritt

Aranesp®
(Darbepoetin alfa)

 **BLINCYTO®**
(blinatumomab) infusion


IMLYGIC®
(talimogene laherparepvec)
INTRALESIONAL INJECTION

Kyprolis®
(carfilzomib) Powder
for solution
for infusion


LUMYKRAS®
(sotorasib)


MVASI®
(Bevacizumab)

 **Neulasta®**
(Pegfilgrastim)

 **Nplate®**
romiplostim

Von Anfang an – 100% human 
Vectibix®
Panitumumab

XGEVA®
(denosumab)

NOTES

[illegible]



Fight your cancer within the MINUTE

MOLECULAR INTERNAL NUCLIDE THERAPY

MINUTEmedical • Hoerlgasse 14/5 • 1090 Vienna • Austria • www.minute-medical.com

Leading a new era in radiopharmaceuticals

Telix, a commercial-stage biopharmaceutical company focused on the development and commercialisation of therapeutic and diagnostic ('theranostic') radiopharmaceuticals.

Telix's extensive pipeline for urologic oncology (prostate and kidney), neuro-oncology (glioma), musculoskeletal oncology (sarcoma) and bone marrow conditioning is underpinned by a strong global supply, manufacturing and distribution network.



©2025 Telix innovations SA. Rue de Hermée 255, 4040 Herstal, Belgium. The Telix name and logo are trademarks of Telix Pharmaceuticals Limited and its affiliates. All rights reserved. Veeva Code: AT--2500001. Date of diffusion: April 2025. For any medical request, please contact medinfo@telixpharma.com

